The U.S. Food and Drug Administration approved BioCryst Pharmaceuticals Inc.’s Orladeyo (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and young patients 12 years and older.
For years, you’ve been replacing your patient’s testosterone. Maybe it’s time to consider replacing how it’s delivered. While there have been frequent, and prominent, new products developed for treating hypogonadism in the last 20 years, one particular type of option has been scarce – and it may be the one that patients want and/or prefer. […]
A therapy jointly developed by Switzerland’s Roche Holding AG and Cambridge, Mass.-based Blueprint Medicines Corp. was approved by the U.S. health regulator for the treatment of patients with a type of non-small cell lung cancer (NSCLC).
The U.S. Food and Drug Administration approved an oral treatment from Roche Holding AG and PTC Therapeutics Inc. for spinal muscular atrophy in adults and children two months and above.
The U.S. Food and Drug Administration approved GlaxoSmithKline Plc’s HIV drug Rukobia to treat adult patients who have run out of treatment options.
The U.S. Food and Drug Administration greenlit Karyopharm Therapeutics’ Xpovio (selinexor) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) under accelerated approval.
The U.S. Food and Drug Administration approved Michigan-based Esperion’s oral, once-daily, non-statin LDL-cholesterol lowering medicine Nexletol (bempedoic acid).
The U.S. Food and Drug Administration approved Blueprint Medicines Corp.’s oral therapy to treat a rare form of cancer that affects the stomach and small intestine.